However, the KRAS p.G12C mutation only occurs in 1% to 3% of CRC (45), and other more common KRAS mutations in CRC remain “undruggable.” The high affinity of KRAS for its substrate GTP and the high concentration of GTP in the cells make it exceedingly unlikely that a successful competitive KRAS inhibitor can be developed (46). The gene discussed is KRAS; the disease is colorectal carcinoma.